76706-55-3
中文名稱
粘噻唑
英文名稱
MYXOTHIAZOL
CAS
76706-55-3
分子式
C25H33N3O3S2
分子量
487.68
MOL 文件
76706-55-3.mol
更新日期
2023/03/20 15:41:19
76706-55-3 結(jié)構(gòu)式
基本信息
中文別名
粘噻唑 英文別名
MyxothiazoMYXOTHIAZOL
5-dimethoxy-4-methyl-
myxothiazolfrommyxobacterium
MYXOTHIAZOL, VIAL WITH 10 MG*
MYXOTHIAZOL FROM MYXOBACTERIUM 95%
MYXOTHIAZOL, FROM MYXOCOCCUS FULVUS
myxothiazol from myxobacterium*myxococcus fulvus
7-(2’-(1,6-dimethyl-2,4-heptadienyl)(2,4’-bithiazol)-4-yl)-6-heptadienamide
2,6-Heptadienamide, 7-(2'-(1,6-dimethyl-2,4-heptadienyl)(2,4'-bithiazol)-4-yl)-3,5-dimethoxy-4-methyl-
物理化學(xué)性質(zhì)
沸點(diǎn)679.6±65.0 °C(Predicted)
密度1.158±0.06 g/cm3(Predicted)
儲(chǔ)存條件-20°C
溶解度氯仿：可溶9.80 - 10.20mg/mL，透明，無(wú)色至黃色
酸度系數(shù)(pKa)14.07±0.50(Predicted)
形態(tài)Solid
顏色White to off-white
安全數(shù)據(jù)
警示詞危險(xiǎn)
危險(xiǎn)性描述H300
防范說(shuō)明P264-P270-P301+P310-P405-P501
危險(xiǎn)品標(biāo)志T+
危險(xiǎn)類別碼28
安全說(shuō)明28-36/37-45
危險(xiǎn)品運(yùn)輸編號(hào)UN 3462 6.1/PG 1
WGK Germany3
RTECS號(hào)QH7580000
F10
危險(xiǎn)等級(jí)6.1(b)
包裝類別III
粘噻唑價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-112177 | 粘噻唑 Myxothiazol | 76706-55-3 | 1 mg | 4200元 |
| 2023/03/20 | HY-112177 | 粘噻唑 Myxothiazol | 76706-55-3 | 5 mg | 10500元 |
常見(jiàn)問(wèn)題列表
生物活性
Myxothiazol 是一種抗真菌抗生素，是線粒體電子傳遞鏈復(fù)合體 Ⅲ (complex III or bc1 complex) 抑制劑。Myxothiazol 在0.01~3 μg/ml 濃度范圍內(nèi)可抑制許多酵母菌和真菌的生長(zhǎng)。體外研究
Myxothiazol inhibits the growth of many yeasts and fungi at concentrations between 0.01 and 3 μg/ml.
Myxothiazol binds to the ubiquinol oxidation site Qo of complex III and blocks electron transfer from ubiquinol to cytochrome b and thus inhibits complex III activity.
體內(nèi)研究
Myxothiazol (i.p.; 0.56 mg/kg; daily for 4 days)-induced complex III inhibition can be induced in mice for four days in a row without overt hepatotoxicity or lethality.
| Animal Model: | C57Bl/J6 mice |
| Dosage: | 0.56 mg/kg |
| Administration: | I.p.; 24 hours intervals for at most 4 times |
| Result: | A reversible complex III activity decrease to 50% of control value occurred at 2 h post-injection. At 74 h only minor histological changes in the liver were found, supercomplex formation was preserved and no significant changes in the expression of genes indicating hepatotoxicity or inflammation were found. |